Replies to post #341882 on The Hunt for the Next 10 Bagger

[The Rainmaker]

Four times in last 10 months BMOD moved up in anticipation of Phase II results. Phase II results being released any day now.

1) August 1 2009 BMOD runs from .02 to .30

Biomoda Study Will Screen 500 New Mexico Veterans for Lung Cancer

SANTA FE, N.M., Aug. 4, 2009 (GLOBE NEWSWIRE) -- Biomoda, Inc. (OTCBB:BMOD), the New Mexico Department of Veterans Services, and the New Mexico Institute of Mining and Technology (NM Tech) appeared before the State Legislature's Interim Tobacco Settlement Committee to report that 500 New Mexico veterans have committed to participate in a state-funded program for the detection of early-stage lung cancer based on Biomoda's proprietary technology.

2) August 14, 2009 BMOD runs from .15 to .52

10Q Released showing all 500 patients have been enrolled and tested.

The Phase II study is focused on veterans because they are at least 25 percent more likely to develop lung cancer and die from the disease than the general population. As of August 14, 2009, we had recruited more than 500 veterans for the Phase II study and completed screening on 130 individuals. Results will be published at the end of the study period after patient data has been recorded and analyzed. We anticipate the completion of the Phase II study by September 30, 2009.

3) January 2010 BMOD runs from .14 to .35

October PR said FDA submission and Phase II Results by end of January. BMOD ran up in anticipation of end of January results.

4) March 2010 BMOD runs from .19 to .53

Biomoda Awarded Patent Securing Assay Formulation and Use
Tuesday March 2, 2010. People start expecting Phase II results shortly.


5) June 2010 BMOD runs from .16 to ??????????????

Phase II Results coming in June per their filings.

Our clinical study designers determined that an additional 44 sputum samples from patients who have received a diagnosis of lung cancer but have not yet begun treatment would provide the data required to complete the Phase II trial. The addition of these 44 samples will provide a statistically significant analysis of sensitivity and specificity of the assay for detecting lung cancer. In December 2009, we signed a consulting agreement with Christiana Care Health Services for sputum sample procurement. The Helen F. Graham Cancer Center will recruit a cohort of patients diagnosed with lung cancer to participate in the final stage of the Phase II pilot study of the investigational CyPath® assay, an early-stage diagnostic test for lung cancer. We anticipate contracting with additional medical institutions to secure necessary sputum samples from lung cancer patients. Completion of sample procurement is expected by the end of May 2010 after which time the results will be analyzed by the principal investigator and published in accordance with standard peer review and publishing guidelines for studies of this type.